CEO Lawrence Klein was paid $3,356,050 in fiscal year 2025, ↑ up 544.3% from fiscal year 2024, the 27th percentile of its disclosed peer group (SEC filing 0001213900-26-045159 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,356,050 ↑ Lawrence Klein total, FY2025 | 27th CEO pay percentile vs peers | — CEO-to-median pay ratio | 98.01% Say-on-pay support, latest vote |
You have just read Oruka Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper ORKA reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ORKA's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Lawrence Klein | $624,000 | $0 | $0 | $2,275,390 | $446,160 | $0 | $10,500 | $3,356,050 |
| Chief Executive Officer | ||||||||
| Joana Goncalves | 474,000 | 0 | 0 | 1,607,613 | 246,480 | 0 | 10,500 | 2,338,593 |
| Chief Medical Officer | ||||||||
| Paul Quinlan | 474,000 | 0 | 0 | 1,607,613 | 246,480 | 0 | 10,500 | 2,338,593 |
| General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Lawrence Klein | $3,356,050 | $520,911 | — | ↑ +2,835,139 |
| Joana Goncalves | 2,338,593 | 317,986 | — | ↑ +2,020,607 |
| Paul Quinlan | 2,338,593 | 310,445 | — | ↑ +2,028,148 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
Each company listed discloses ORKA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ORKA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Paul Quinlan | General Counsel | $2,338,593 |
| Joana Goncalves | Chief Medical Officer | $2,338,593 |
| Lawrence Klein | CEO | $3,356,050 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Cameron Turtle | Former director (through FY2025) | $209,307 |
| Carl Dambkowski | Independent Director | $200,567 |
| Chris Martin | Independent Director | $803,950 |
| Kristine Ball | Independent Director | $213,067 |
| Peter Harwin | Independent Director | $209,067 |
| Samarth Kulkarni | Independent Director | $234,067 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Lawrence Klein | Option | 177,292 | 12.5 | — |
| Lawrence Klein | Option | 949,966 | 7.8 | — |
| Lawrence Klein | RSU | 461,683 | — | 13,993,612 |
| Joana Goncalves | Option | 133,329 | 6.84 | — |
| Joana Goncalves | Option | 116,662 | 7.8 | — |
| Joana Goncalves | Option | 125,260 | 12.5 | — |
| Paul Quinlan | Option | 133,329 | 6.84 | — |
| Paul Quinlan | Option | 58,331 | 7.8 | — |
| Paul Quinlan | Option | 125,260 | 12.5 | — |
In December 2024, our Compensation Committee adopted a compensation philosophy to frame future compensation decisions for the Company. Under this philosophy, compensation positioning is used to attract and retain key employees for the Company’s continued success and growth. While market data is helpful to the Compensation Committee in setting the compensation framework and guiding decisions, other factors such as Company strategy, stockholder feedback, tenure, performance and criticality are also considered. The compensation philosophy serves as the foundation to reinforce the Company’s business strategy and desired culture, while balancing internal and external alignment.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards LLC |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 43,033,967 | 875,114 | 73,091 | 98.01% | Passed |
| 2025 | 2025-06-02 | 25,824,834 | 88,740 | 136,631 | 99.66% | Passed |
| 2022 | 2022-12-15 | 5,301,245 | 456,787 | 59,755 | 92.07% | Passed |
| 2021 | 2021-07-08 | 1,395,198 | 750,488 | 108,445 | 65.02% | Passed |
| 2020 | 2020-12-10 | 1,403,331 | 362,698 | 59,731 | 76.86% | Passed |
| 2016 | 2016-06-09 | 5,353,633 | 62,999 | 22,882 | 98.42% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-02 | 98.01%a |
| 2025 | 2025-06-02 | 99.66%b |
| 2022 | 2022-12-15 | 92.07%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Chris MartinIndependent · Audit · Compensation · Newly elected | $3,423 | — | $800,527 | — | — | $803,950 |
| Samarth KulkarniIndependent · Compensation · Nominating | 81,000 | — | 153,067 | — | — | 234,067 |
| Kristine BallIndependent · Audit (Chair) · Nominating · Compensation | 60,000 | — | 153,067 | — | — | 213,067 |
| Cameron TurtleIndependent · Audit · Compensation · Departed during FY | 56,240 | — | 153,067 | — | — | 209,307 |
| Peter HarwinIndependent · Compensation · Nominating (Chair) | 56,000 | — | 153,067 | — | — | 209,067 |
| Carl DambkowskiIndependent · Audit | 47,500 | — | 153,067 | — | — | 200,567 |
| Lawrence KleinEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $304,163 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $304,163 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Oruka Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Oruka Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Janux Therapeutics | 2025 | David Campbell | $680,000 | $0 | $12,459,031 | $367,200 | $13,506,231 |
| 2 | CARGO Therapeutics | 2024 | Gina Chapman | 630,800 | 0 | 8,155,520 | 363,800 | 9,300,120 |
| 3 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 4 | Astria Therapeutics | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 5 | Celldex Therapeutics | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 6 | Entrada Therapeutics | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 7 | Lexeo Therapeutics | 2025 | R. Nolan Townsend | 632,700 | 1,493,488 | 1,165,982 | 347,985 | 3,650,940 |
| 8 | Contineum Therapeutics | 2025 | Carmine Stengone | 655,620 | 0 | 2,291,640 | 450,739 | 3,409,448 |
| 9 | Oruka Therapeutics | 2025 | Lawrence Klein | 624,000 | 0 | 2,275,390 | 446,160 | 3,356,050 |
| 10 | Longboard Pharmaceuticals | 2023 | Kevin Lind | 610,000 | 0 | 986,934 | 442,860 | 2,053,804 |
| 11 | Kyverna Therapeutics | 2025 | Warner Biddle | 625,000 | 0 | 543,804 | 468,750 | 1,814,980 |
| 12 | Apogee Therapeutics | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Oruka Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards LLC |
| Apogee Therapeutics | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Astria Therapeutics | not disclosed | Option 100 | not disclosed | Aon |
| CARGO Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Celldex Therapeutics | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Contineum Therapeutics | not disclosed | Option 100 | not disclosed | Alpine |
| Entrada Therapeutics | not disclosed | not disclosed | No | Pay Governance |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Kyverna Therapeutics | not disclosed | Option 100 | not disclosed | Aon plc |
| Lexeo Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Longboard Pharmaceuticals | not disclosed | Option 100 | not disclosed | Frederic W. Cook & Co. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Lawrence Klein | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Executive Compensation”. As printed: 3,356,050. Filing ↗machine: r1 · c12 · span 534154–534163 |
| 2 | Section 01, Joana Goncalves | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Executive Compensation”. As printed: 2,338,593. Filing ↗machine: r4 · c12 · span 554391–554400 |
| 3 | Section 01, Paul Quinlan | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Executive Compensation”. As printed: 2,338,593. Filing ↗machine: r7 · c12 · span 574643–574652 |
| 4 | Section 08, Chris Martin | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Director Compensation”. As printed: 803,950. Filing ↗machine: span 424591–424970 |
| 5 | Section 08, Samarth Kulkarni | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Director Compensation”. As printed: 234,067. Filing ↗machine: span 416564–416943 |
| 6 | Section 08, Kristine Ball | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Director Compensation”. As printed: 213,067. Filing ↗machine: span 404768–405147 |
| 7 | Section 08, Cameron Turtle | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Director Compensation”. As printed: 209,307. Filing ↗machine: span 420589–420968 |
| 8 | Section 08, Peter Harwin | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Director Compensation”. As printed: 209,067. Filing ↗machine: span 412637–413016 |
| 9 | Section 08, Carl Dambkowski | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Director Compensation”. As printed: 200,567. Filing ↗machine: span 408694–409073 |
| 10 | Section 08, Lawrence Klein | DEF 14A | 2026-04-17 | 0001213900-26-045159 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 06, 2026 vote | Form 8-K | 2026-06-04 | 0001213900-26-065294 | Item 5.07 · say-on-pay result. As reported: 98.01% (votes for as printed: 43,033,967). Filing ↗ |
| 12 | Section 06, 2025 vote | Form 8-K | 2025-06-03 | 0001213900-25-050756 | Item 5.07 · say-on-pay result. As reported: 99.66% (votes for as printed: 25,824,834). Filing ↗ |
| 13 | Section 06, 2022 vote | Form 8-K | 2022-12-19 | 0000950170-22-026739 | Item 5.07 · say-on-pay result. As reported: 92.07% (votes for as printed: 5,301,245). Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 09b board cost (computed) | Computed | — | — | Cash 304,163 + equity 0 + all other 0 = 304,163, summed across the director compensation table rows.machine: formula: Σ = 304,163 |
| 16 | Janux Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187095 | CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. Filing ↗machine: r2 · c22 · span 571399–571409 |
| 17 | CARGO Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001193125-25-103786 | CEO total compensation as printed in CARGO Therapeutics's own proxy. As printed: 9,300,120. Filing ↗machine: r2 · c31 · span 289578–289587 |
| 18 | Kymera Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 19 | Astria Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-28 | 0001104659-25-040180 | CEO total compensation as printed in Astria Therapeutics's own proxy. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460 |
| 20 | Celldex Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050884 | CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866 |
| 21 | Entrada Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001689375-26-000021 | CEO total compensation as printed in Entrada Therapeutics's own proxy. As printed: 3,837,737. Filing ↗machine: t12 · r2 · c14 · span 336891–336900 |
| 22 | Lexeo Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-193930 | CEO total compensation as printed in Lexeo Therapeutics's own proxy. As printed: 3,650,940. Filing ↗machine: r2 · c21 · span 463876–463885 |
| 23 | Contineum Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028881 | CEO total compensation as printed in Contineum Therapeutics's own proxy. As printed: 3,409,448. Filing ↗machine: span 271162–271171 |
| 24 | Oruka Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001213900-26-045159 | CEO total compensation as printed in Oruka Therapeutics's own proxy. As printed: 3,356,050. Filing ↗machine: r1 · c12 · span 534154–534163 |
| 25 | Longboard Pharmaceuticals, Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044023 | CEO total compensation as printed in Longboard Pharmaceuticals's own proxy. As printed: 2,053,804. Filing ↗machine: r2 · c22 · span 476646–476655 |
| 26 | Kyverna Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-13 | 0001193125-26-152835 | CEO total compensation as printed in Kyverna Therapeutics's own proxy. As printed: 1,814,980. Filing ↗machine: r2 · c26 · span 547940–547949 |
| 27 | Apogee Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177342 | CEO total compensation as printed in Apogee Therapeutics's own proxy. As printed: 1,291,500. Filing ↗ |
| 28 | Section 10a, Janux Therapeutics reciprocity | DEF 14A | — | 0001193125-26-187095 | Janux Therapeutics's most recent proxy was read; its disclosed peer group does not include Oruka Therapeutics. Filing ↗ |
| 29 | Section 10a, Astria Therapeutics reciprocity | DEF 14A | — | 0001104659-25-040180 | Astria Therapeutics's most recent proxy was read; its disclosed peer group does not include Oruka Therapeutics. Filing ↗ |
| 30 | Section 10a, Celldex Therapeutics reciprocity | DEF 14A | — | 0001104659-26-050884 | Celldex Therapeutics's most recent proxy was read; its disclosed peer group does not include Oruka Therapeutics. Filing ↗ |
| 31 | Section 10a, Kymera Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics's most recent proxy was read; its disclosed peer group does not include Oruka Therapeutics. Filing ↗ |
| 32 | Section 10a, Contineum Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028881 | Contineum Therapeutics's most recent proxy was read; its disclosed peer group does not include Oruka Therapeutics. Filing ↗ |
| 33 | Section 10a, Apogee Therapeutics reciprocity | DEF 14A | — | 0001193125-26-177342 | Apogee Therapeutics's most recent proxy was read; its disclosed peer group does not include Oruka Therapeutics. Filing ↗ |